HFA Premium Access

Baseline characteristics, treatment dosage, and clinical outcomes of post-acute HFrEF patients initiated with Sacubitril/Valsartan

Congress Presentation

About the speaker

Ms Huai-Wen Liang

E-Da hospital, Kaohsiung (Taiwan)
0 follower

56 more presentations in this session

Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.

Speaker: Doctor L. Buttigieg (Msida, MT)

Thumbnail

Sacubitril valsartan, a multicentric experience

Speaker: Mr F. Cortes (Seville, ES)

Thumbnail

Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy

Speaker: Professor B. Kanazirev (Varna, BG)

Thumbnail

Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy

Speaker: Associate Professor C. Hsu (Taipei, TW)

Thumbnail

Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy

Speaker: Doctor C. Hsieh (Taipei, TW)

Thumbnail

Access the full session

Poster Session 3 - Chronic Heart Failure – Treatment

Speakers: Ms H. Liang, Doctor L. Buttigieg, Mr F. Cortes, Professor B. Kanazirev, Associate Professor C. Hsu...
Thumbnail

About the event

Image

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb